10-K Filing

Oruka Therapeutics, Inc. CIK: 907654 FY 2011

Filing Information

Form Type	10-K
Accession Number	`0001193125-12-134451`
Period End Date	20111231
Filing Date	20120327
Fiscal Year	2011
Fiscal Period	FY
XBRL Instance	abio-20111231.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 54 Income Statement 47 Cash Flow Statement 94 Stockholders Equity 51

Balance Sheet 54 line items

Line Item	Tag	Value	Unit	Period
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$5.94M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$7.76M	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$7.03M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	12.18M	shares	Point-in-time
Other current assets	`OtherAssetsCurrent`	$137.00K	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	8.83M	shares	Point-in-time
Other current assets	`OtherAssetsCurrent`	$269.00K	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	12.18M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$7.16M	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	8.83M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$6.21M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$690.00K	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$66.00K	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$224.00K	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$304.00K	USD	Point-in-time
Total assets	`Assets`	$8.16M	USD	Point-in-time
Total assets	`Assets`	$6.50M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$388.00K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$260.00K	USD	Point-in-time
Accrued compensation and employee benefits	`EmployeeRelatedLiabilitiesCurrent`	$111.00K	USD	Point-in-time
Accrued compensation and employee benefits	`EmployeeRelatedLiabilitiesCurrent`	$175.00K	USD	Point-in-time
Accrued expenses and other liabilities	`OtherLiabilitiesCurrent`	$506.00K	USD	Point-in-time
Accrued expenses and other liabilities	`OtherLiabilitiesCurrent`	$350.00K	USD	Point-in-time
Deferred rent, current portion	`DeferredRentCreditCurrent`	$33.00K	USD	Point-in-time
Deferred rent, current portion	`DeferredRentCreditCurrent`	$121.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$754.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.19M	USD	Point-in-time
Deferred rent, net of current portion	`DeferredRentCreditNoncurrent`	$16.00K	USD	Point-in-time
Deferred rent, net of current portion	`DeferredRentCreditNoncurrent`	$195.00K	USD	Point-in-time
Total liabilities	`Liabilities`	$770.00K	USD	Point-in-time
Total liabilities	`Liabilities`	$1.39M	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Common stock, $0.001 par value; 100 million shares authorized at December 31, 2011 and December 31, 2010; 12,182,999 and 8,834,535 shares issued and outstanding at December 31, 2011 and December 31, 2010, respectively	`CommonStockValue`	$12.00K	USD	Point-in-time
Common stock, $0.001 par value; 100 million shares authorized at December 31, 2011 and December 31, 2010; 12,182,999 and 8,834,535 shares issued and outstanding at December 31, 2011 and December 31, 2010, respectively	`CommonStockValue`	$9.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$69.39M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$65.07M	USD	Point-in-time
Deficit accumulated during the development stage	`RetainedEarningsAccumulatedDeficit`	$-63.67M	USD	Point-in-time
Deficit accumulated during the development stage	`RetainedEarningsAccumulatedDeficit`	$-58.31M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$-678.00K	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$-19.69M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$-619.00K	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$-38.18M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$-115.00K	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$6.77M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$-5.74M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$5.73M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$7.41M	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$6.50M	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$8.16M	USD	Point-in-time

Income Statement 47 line items

Line Item	Tag	Value	Unit	Period
Research and development	`ResearchAndDevelopmentExpense`	$2.31M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$41.59M	USD	40 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$3.11M	USD	Annual
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$39.36M	USD	40 Qtrs
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$5.05M	USD	Annual
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$6.07M	USD	Annual
Merger transaction costs	`BusinessCombinationAcquisitionRelatedCosts`	$5.47M	USD	40 Qtrs
Restructuring expense, net	`RestructuringCharges`	$2.41M	USD	40 Qtrs
Loss on impairment of in-process research and development	`ImpairmentOfIntangibleAssetsExcludingGoodwill`	$6.00M	USD	40 Qtrs
Total costs and expenses	`OperatingExpenses`	$9.18M	USD	Annual
Total costs and expenses	`OperatingExpenses`	$7.36M	USD	Annual
Total costs and expenses	`OperatingExpenses`	$94.82M	USD	40 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-94.82M	USD	40 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-7.36M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-9.18M	USD	Annual
Gain on assignment of patent rights	`GainLossOnAssignmentOfPatentRights`	$2.00M	USD	Annual
Gain on assignment of patent rights	`GainLossOnAssignmentOfPatentRights`	$2.00M	USD	40 Qtrs
Gain on bargain purchase	`BusinessCombinationBargainPurchaseGainRecognizedAmount`	$25.28M	USD	40 Qtrs
Interest and other income	`InterestAndOtherIncome`	$2.03M	USD	40 Qtrs
Interest and other income	`InterestAndOtherIncome`	$763.00K	USD	Annual
Interest and other income	`InterestAndOtherIncome`	$2.00K	USD	Annual
Interest and other expense	`InterestExpenseDebt`	$5.00K	USD	Annual
Interest and other expense	`InterestExpenseDebt`	$8.00K	USD	Annual
Interest and other expense	`InterestExpenseDebt`	$439.00K	USD	40 Qtrs
Loss before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-65.95M	USD	40 Qtrs
Loss before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-8.42M	USD	Annual
Loss before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-5.36M	USD	Annual
Benefit from income taxes	`IncomeTaxExpenseBenefit`	$-2.28M	USD	40 Qtrs
Net loss	`NetIncomeLoss`	$-1.46M	USD	Annual
Net loss	`NetIncomeLoss`	$-5.36M	USD	Annual
Net loss	`NetIncomeLoss`	$-5.24M	USD	Annual
Net loss	`NetIncomeLoss`	$-116.00K	USD	8 Qtrs
Net loss	`NetIncomeLoss`	$-511.00K	USD	Annual
Net loss	`NetIncomeLoss`	$-19.43M	USD	Annual
Net loss	`NetIncomeLoss`	$-9.14M	USD	Annual
Net loss	`NetIncomeLoss`	$-13.99M	USD	Annual
Net loss	`NetIncomeLoss`	$-8.42M	USD	Annual
Net loss	`NetIncomeLoss`	$-63.67M	USD	40 Qtrs
Less: Accretion of redeemable convertible preferred stock	`PreferredStockAccretionOfRedemptionDiscount`	$245.00K	USD	40 Qtrs
Less: Deemed preferred stock dividend for additional common shares issuable under anti-dilution provisions	`PreferredStockDividendsAndOtherAdjustments`	$781.00K	USD	40 Qtrs
Net loss available to common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-5.36M	USD	Annual
Net loss available to common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-8.42M	USD	Annual
Net loss available to common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-64.70M	USD	40 Qtrs
Basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.99	USD	Annual
Basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.53	USD	Annual
Basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	8.51M	shares	Annual
Basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	10.04M	shares	Annual

Cash Flow Statement 94 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-1.46M	USD	Annual
Net loss	`NetIncomeLoss`	$-5.36M	USD	Annual
Net loss	`NetIncomeLoss`	$-5.24M	USD	Annual
Net loss	`NetIncomeLoss`	$-116.00K	USD	8 Qtrs
Net loss	`NetIncomeLoss`	$-511.00K	USD	Annual
Net loss	`NetIncomeLoss`	$-19.43M	USD	Annual
Net loss	`NetIncomeLoss`	$-9.14M	USD	Annual
Net loss	`NetIncomeLoss`	$-13.99M	USD	Annual
Net loss	`NetIncomeLoss`	$-8.42M	USD	Annual
Net loss	`NetIncomeLoss`	$-63.67M	USD	40 Qtrs
Gain on patent rights assignment	`GainLossOnAssignmentOfPatentRights`	$2.00M	USD	Annual
Gain on patent rights assignment	`GainLossOnAssignmentOfPatentRights`	$2.00M	USD	40 Qtrs
Gain on bargain purchase	`BusinessCombinationBargainPurchaseGainRecognizedAmount`	$25.28M	USD	40 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$338.00K	USD	Annual
Depreciation and amortization	`DepreciationAndAmortization`	$1.74M	USD	40 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$602.00K	USD	Annual
Non-cash interest expense	`PaidInKindInterest`	$211.00K	USD	40 Qtrs
Share-based compensation	`ShareBasedCompensation`	$458.00K	USD	Annual
Share-based compensation	`ShareBasedCompensation`	$2.28M	USD	40 Qtrs
Share-based compensation	`ShareBasedCompensation`	$308.00K	USD	Annual
Issuance of warrants for lease termination	`IssuanceOfStockAndWarrantsForServicesOrClaims`	$377.00K	USD	40 Qtrs
Accretion of liabilities	`AccretionExpense`	$152.00K	USD	40 Qtrs
Impairment of property and equipment	`ImpairmentOfLongLivedAssetsHeldForUse`	$125.00K	USD	40 Qtrs
Impairment of in-process research and development	`ImpairmentOfIntangibleAssetsExcludingGoodwill`	$6.00M	USD	40 Qtrs
Write-off of deferred tax liability	`WriteOffOfDeferredTaxLiability`	$-2.28M	USD	40 Qtrs
Gain on marketable securities available for sale	`MarketableSecuritiesGainLoss`	$263.00K	USD	Annual
Gain on marketable securities available for sale	`MarketableSecuritiesGainLoss`	$263.00K	USD	40 Qtrs
(Gain) loss from disposal of property and equipment	`GainLossOnSaleOfPropertyPlantEquipment`	$-16.00K	USD	Annual
(Gain) loss from disposal of property and equipment	`GainLossOnSaleOfPropertyPlantEquipment`	$4.00K	USD	Annual
(Gain) loss from disposal of property and equipment	`GainLossOnSaleOfPropertyPlantEquipment`	$-83.00K	USD	40 Qtrs
Other, net	`OtherNoncashIncomeExpense`	$-267.00K	USD	40 Qtrs
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$-2.54M	USD	40 Qtrs
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$-58.00K	USD	Annual
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$-14.00K	USD	Annual
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$-7.25M	USD	40 Qtrs
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$-80.00K	USD	Annual
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$-84.00K	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-1.93M	USD	40 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-128.00K	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-145.00K	USD	Annual
Accrued expenses and other liabilities	`IncreaseDecreaseInOtherOperatingLiabilities`	$-18.98M	USD	40 Qtrs
Accrued expenses and other liabilities	`IncreaseDecreaseInOtherOperatingLiabilities`	$-220.00K	USD	Annual
Accrued expenses and other liabilities	`IncreaseDecreaseInOtherOperatingLiabilities`	$-316.00K	USD	Annual
Deferred rent	`IncreaseDecreaseInDeferredCharges`	$-49.00K	USD	40 Qtrs
Deferred rent	`IncreaseDecreaseInDeferredCharges`	$114.00K	USD	Annual
Deferred rent	`IncreaseDecreaseInDeferredCharges`	$267.00K	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-8.32M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-6.96M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-93.34M	USD	40 Qtrs
Cash received from Merger	`CashAcquiredFromAcquisition`	$30.39M	USD	40 Qtrs
Payment of deferred transaction costs	`OtherPaymentsToAcquireBusinesses`	$1.19M	USD	40 Qtrs
Purchase of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$1.88M	USD	40 Qtrs
Purchase of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$4.00K	USD	Annual
Purchase of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$19.00K	USD	Annual
Proceeds from sale of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$263.00K	USD	Annual
Proceeds from sale of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$15.37M	USD	40 Qtrs
Proceeds from sale of property and equipment	`ProceedsFromSaleOfPropertyPlantAndEquipment`	$25.00K	USD	Annual
Proceeds from sale of property and equipment	`ProceedsFromSaleOfPropertyPlantAndEquipment`	$358.00K	USD	40 Qtrs
Proceeds from sale of property and equipment	`ProceedsFromSaleOfPropertyPlantAndEquipment`	$6.00K	USD	Annual
Proceeds from patent rights assignment	`ProceedsFromSaleOfIntangibleAssets`	$2.00M	USD	40 Qtrs
Proceeds from patent rights assignment	`ProceedsFromSaleOfIntangibleAssets`	-	USD	Annual
Proceeds from patent rights assignment	`ProceedsFromSaleOfIntangibleAssets`	$2.00M	USD	Annual
Net cash provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$265.00K	USD	Annual
Net cash provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$45.05M	USD	40 Qtrs
Net cash provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$2.01M	USD	Annual
Proceeds from issuance of convertible notes payable and related warrants for common stock	`ProceedsFromConvertibleDebt`	$10.84M	USD	40 Qtrs
Proceeds from issuance of bank note payable	`ProceedsFromNotesPayable`	$4.00M	USD	40 Qtrs
Proceeds from stock subject to repurchase	`ProceedsFromIssuanceOfRedeemablePreferredStock`	$38.00K	USD	40 Qtrs
Proceeds from the issuance of preferred stock	`ProceedsFromIssuanceOfPreferredStockAndPreferenceStock`	$32.32M	USD	40 Qtrs
Proceeds from the issuance of common stock	`ProceedsFromIssuanceOfCommonStock`	$12.58M	USD	40 Qtrs
Proceeds from the issuance of common stock	`ProceedsFromIssuanceOfCommonStock`	$4.73M	USD	Annual
Proceeds from the issuance of common stock	`ProceedsFromIssuanceOfCommonStock`	$7.66M	USD	Annual
Repayment of principal on bank note payable	`RepaymentsOfNotesPayable`	$4.00M	USD	40 Qtrs
Repayment of principal on convertible notes payables	`RepaymentsOfConvertibleDebt`	$105.00K	USD	40 Qtrs
Repayment of principal on vendor finance agreement	`RepaymentOfPrincipalOnVendorFinanceAgreement`	-	USD	Annual
Repayment of principal on vendor finance agreement	`RepaymentOfPrincipalOnVendorFinanceAgreement`	$146.00K	USD	40 Qtrs
Repayment of principal on vendor finance agreement	`RepaymentOfPrincipalOnVendorFinanceAgreement`	$146.00K	USD	Annual
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$7.32M	USD	Annual
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$54.23M	USD	40 Qtrs
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$3.87M	USD	Annual
Net (decrease) increase in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-738.00K	USD	Annual
Net (decrease) increase in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-1.08M	USD	Annual
Net (decrease) increase in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$5.94M	USD	40 Qtrs
Cash and cash equivalents, beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$5.94M	USD	Point-in-time
Cash and cash equivalents, beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$7.76M	USD	Point-in-time
Cash and cash equivalents, beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$7.03M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashAndCashEquivalentsAtCarryingValue`	$5.94M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashAndCashEquivalentsAtCarryingValue`	$7.76M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashAndCashEquivalentsAtCarryingValue`	$7.03M	USD	Point-in-time
Interest paid	`InterestPaid`	$5.00K	USD	Annual
Interest paid	`InterestPaid`	$112.00K	USD	40 Qtrs
Accrued interest on notes payable converted to equity	`AccruedInterestOnNotesPayableConvertedToEquity`	$163.00K	USD	40 Qtrs
Warrant issued in connection with credit facility	`WarrantIssuedInConnectionWithCreditFacility`	$111.00K	USD	40 Qtrs
Accrued deferred transaction costs	`AccruedDeferredTransactionCosts`	$482.00K	USD	40 Qtrs

Stockholders Equity 51 line items

Line Item	Tag	Value	Unit	Period
Issuance of common stock, per share	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Issuance of common stock, per share	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Beginning Balance, value	`StockholdersEquity`	$-678.00K	USD	Point-in-time
Beginning Balance, value	`StockholdersEquity`	$-19.69M	USD	Point-in-time
Beginning Balance, value	`StockholdersEquity`	$-619.00K	USD	Point-in-time
Beginning Balance, value	`StockholdersEquity`	$-38.18M	USD	Point-in-time
Beginning Balance, value	`StockholdersEquity`	$-115.00K	USD	Point-in-time
Beginning Balance, value	`StockholdersEquity`	$6.77M	USD	Point-in-time
Beginning Balance, value	`StockholdersEquity`	$-5.74M	USD	Point-in-time
Beginning Balance, value	`StockholdersEquity`	$5.73M	USD	Point-in-time
Beginning Balance, value	`StockholdersEquity`	$7.41M	USD	Point-in-time
Share-based compensation	`StockIssuedDuringPeriodValueShareBasedCompensation`	$308.00K	USD	Annual
Share-based compensation	`StockIssuedDuringPeriodValueShareBasedCompensation`	$845.00K	USD	Annual
Share-based compensation	`StockIssuedDuringPeriodValueShareBasedCompensation`	$458.00K	USD	Annual
Share-based compensation	`StockIssuedDuringPeriodValueShareBasedCompensation`	$50.00K	USD	Annual
Share-based compensation	`StockIssuedDuringPeriodValueShareBasedCompensation`	$39.00K	USD	Annual
Share-based compensation	`StockIssuedDuringPeriodValueShareBasedCompensation`	$545.00K	USD	Annual
Estimated fair value of warrants issued in connection with convertible notes payable	`AdjustmentsToAdditionalPaidInCapitalWarrantIssued`	$399.00K	USD	Annual
Issuance of common stock upon exercise of stock options, for cash, value	`StockIssuedDuringPeriodValueStockOptionsExercised`	$139.00K	USD	Annual
Issuance of common stock upon exercise of stock options, for cash, value	`StockIssuedDuringPeriodValueStockOptionsExercised`	$16.00K	USD	Annual
Issuance of common stock upon exercise of stock options, for cash, value	`StockIssuedDuringPeriodValueStockOptionsExercised`	$114.00K	USD	Annual
Issuance of common stock upon exercise of stock options, for cash, value	`StockIssuedDuringPeriodValueStockOptionsExercised`	$54.00K	USD	Annual
Issuance of common stock upon exercise of stock options, for cash, value	`StockIssuedDuringPeriodValueStockOptionsExercised`	$3.00K	USD	Annual
Net loss	`NetIncomeLoss`	$-1.46M	USD	Annual
Net loss	`NetIncomeLoss`	$-5.36M	USD	Annual
Net loss	`NetIncomeLoss`	$-5.24M	USD	Annual
Net loss	`NetIncomeLoss`	$-116.00K	USD	8 Qtrs
Net loss	`NetIncomeLoss`	$-511.00K	USD	Annual
Net loss	`NetIncomeLoss`	$-19.43M	USD	Annual
Net loss	`NetIncomeLoss`	$-9.14M	USD	Annual
Net loss	`NetIncomeLoss`	$-13.99M	USD	Annual
Net loss	`NetIncomeLoss`	$-8.42M	USD	Annual
Net loss	`NetIncomeLoss`	$-63.67M	USD	40 Qtrs
Deemed preferred stock dividend for additional common shares issuable under anti-dilution provision	`DividendsPreferredStockStock`	$781.00K	USD	Annual
Conversion of preferred stock and convertible notes and related accrued interest, value	`StockIssuedDuringPeriodValueConversionOfConvertibleSecurities`	$33.78M	USD	Annual
Restricted stock release from restriction	`AdjustmentToAdditionalPaidInCapitalRestrictedStockReleaseFromRestriction`	$75.00K	USD	Annual
Conversion of warrants for preferred stock	`AdjustmentToAdditionalPaidInCapitalConversionOfWarrantsForPreferredStock`	$36.00K	USD	Annual
Merger with Nuvelo, Inc., value	`StockIssuedDuringPeriodValueAcquisitions`	$11.91M	USD	Annual
Issuance of common stock under employee stock purchase plan and upon vesting of restricted stock units, value	`StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan`	$2.00K	USD	Annual
Estimated fair value of warrants issued in connection with lease termination	`AdjustmentToAdditionalPaidInCapitalEstimatedFairValueOfWarrantsIssued`	$377.00K	USD	Annual
Issuance of common stock for cash, net of offering costs, value	`StockIssuedDuringPeriodValueNewIssues`	$7.18M	USD	Annual
Issuance of common stock for cash, net of offering costs, value	`StockIssuedDuringPeriodValueNewIssues`	$4.02M	USD	Annual
Ending Balance, value	`StockholdersEquity`	$-678.00K	USD	Point-in-time
Ending Balance, value	`StockholdersEquity`	$-19.69M	USD	Point-in-time
Ending Balance, value	`StockholdersEquity`	$-619.00K	USD	Point-in-time
Ending Balance, value	`StockholdersEquity`	$-38.18M	USD	Point-in-time
Ending Balance, value	`StockholdersEquity`	$-115.00K	USD	Point-in-time
Ending Balance, value	`StockholdersEquity`	$6.77M	USD	Point-in-time
Ending Balance, value	`StockholdersEquity`	$-5.74M	USD	Point-in-time
Ending Balance, value	`StockholdersEquity`	$5.73M	USD	Point-in-time
Ending Balance, value	`StockholdersEquity`	$7.41M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.